Certified Advisory Corp’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Certified Advisory Corp’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-43	Closed	-$1K	–	791
2021 Q1	$1K	Buy	+43	New	+$1.95K	﹤0.01%	771
2020 Q2	$14K	Buy	333 +200	+150%	+$13.5K	﹤0.01%	505
2020 Q1	$11K	Buy	+133	New	+$10.6K	﹤0.01%	520

Other funds holding EVFM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Certified Advisory Corp's EVFM Position: Q2 2021 in Review

Certified Advisory Corp sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2021, closing a stake of 43 shares — an estimated $1K sold.

Certified Advisory Corp first reported a position in EVFM in Q1 2020 and held it in 3 quarters. The position peaked at $14K in Q2 2020. 81 funds tracked by Wall St. Rank hold EVFM as of Q2 2021.

Certified Advisory Corp reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Certified Advisory Corp sold 43 Evofem Biosciences, Inc. Common Stock shares in Q2 2021, an estimated $1K.
Certified Advisory Corp first reported a position in Evofem Biosciences, Inc. Common Stock in Q1 2020 and held it in 3 quarters.
Certified Advisory Corp's Evofem Biosciences, Inc. Common Stock position peaked at $14K in Q2 2020.
81 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2021.

Based on Certified Advisory Corp's 13F filing for Q2 2021, filed 16 Aug 2021.